Brain (Nervous System) CancersNCT05859659
Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
An observational study of Brain (Nervous System) Cancers and Glioma, run by Yaou Liu at 1 site in China.
Trial summary
Primary central nervous system (CNS) tumors, the vast majority (>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence… Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Brain (Nervous System) Cancers, Glioma, Brain Tumor
- What is being tested?
- This study does not intervene in this process.
- How many people
- 70,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2022to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: To reflect the daily practices, this study includes all patients with diffuse glioma at the beginning of the study.
Who may be able to join
- (1) a clear diagnosis of glioma based on pathological results;
- (2) The MRI sequence is complete and there are no obvious artifacts in the image;
- (3) The patient signs an informed consent form
Who cannot join
- (1) Suffering from other neurological diseases;
- (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;
- (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;
- (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100053
Yaou Liu, PhD, yaouliu80@163.com
About this study
Primary central nervous system (CNS) tumors, the vast majority (>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence due to the substantial high rates of morbidity and mortality. Among which, glioma disease is the most common primary malignant CNS tumor, while the glioblastoma that showed the highest degree of malignancy and the worst prognosis accounts for 70-75%.
The construction goal of this project is to construct a multivariate retrospective CNS tumor database (over 50,000 cases, including 10,000 glioma) integrating clinical information, preoperative magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (3,000 cases) integrating advanced magnetic resonance sequences and postoperative follow-up. It aims to form a standardized database integrating magnetic resonance imaging, pathological results, and clinical-prognostic information.
Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation, tumor classification and labeling process, and the expert consensus on database construction and use management of CNS tumors were established. We aim to form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms. On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of CNS tumor diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated, and providing comprehensive resources of retrospective data and prospective cohorts for large-scale reasearches, such as classification or treatment intervention predictions.
- Conditions
- Brain (Nervous System) Cancers, Glioma, Brain Tumor
- Being tested
- This study does not intervene in this process.
- Medical subject headings
- Neurologic Manifestations, Neoplasms, Glioma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
This study does not intervene in this process.Diagnostic test
This study does not intervene in this process.
| Study group | Role | What they receive |
|---|---|---|
| Retrospective database of CNS tumors included in the WHO classification (2021) | The subtypes of brain tumors were confirmed by the postoperative histopathology or molecular pathology Receives: Diagnostic Test: This study does not intervene in this process. | |
| Prospective cohort of suspected CNS tumors | Intracranial mass lesion comfirmed by preoperative neuroimaging Receives: Diagnostic Test: This study does not intervene in this process. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Establish standardized clinical-MRI-molecular markers database for CNS tumors
Collecting at least 50,000 retrospective data of CNS tumors patients, including preoperative brain MRI, clinical infromations, histopathology resuluts, and molecular markers, to establish a multi-modal clinical-MRI-molecular database
Measured: 2022.06-2023.12
Establish prospective brain tumor cohort with multiomics information
Prospectively include at leaset 10,000 patients with brain space occupying lesions comfirmed by neuroimaging, recording their pre- and postoperative brain MRI, imaging diagnosis, histopathology or molecular pathology results, clinical intervention, treatment effect, and survival time.
Measured: 2022.06.01-2030.12.31
Secondary outcomes (1)
Accurately predicting the molecular and survival of glioma patients based on a deep learning model
Build a MRI-based deep-learning model to predict molecular and survival on glioma.
Measured: 2022.01-2024.12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2023
- Study start1 Jan 2022
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain (Nervous System) CancersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 70,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yaou Liu
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Yaou Liu, Beijing Tiantan Hospital
- Investigators
- Yaou Liu, Doctor, Principal investigator, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05859659
- Sponsor's protocol ID
- KY2022-078-04
- Status last verified
- Mar 2026
- First submitted
- 5 May 2023
- Last updated
- 9 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Clinical and MR data can be shared.
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
- ClinicalTrials.gov ID
- NCT05859659
- Acronym / sponsor ID
- KY2022-078-04
- Conditions
- Brain (Nervous System) Cancers, Glioma, Brain Tumor
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 70,000 participants (estimated)
- Lead sponsor
- Yaou LiuUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 16 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary central nervous system (CNS) tumors, the vast majority (>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence due to the substantial high rates of morbidity and mortality. Among which, glioma disease is the most common primary malignant CNS tumor, while the glioblastoma that showed the highest degree of malignancy and the worst prognosis accounts for 70-75%.
The construction goal of this project is to construct a multivariate retrospective CNS tumor database (over 50,000 cases, including 10,000 glioma) integrating clinical information, preoperative magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (3,000 cases) integrating advanced magnetic resonance sequences and postoperative follow-up. It aims to form a standardized database integrating magnetic resonance imaging, pathological results, and clinical-prognostic information.
Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation, tumor classification and labeling process, and the expert consensus on database construction and use management of CNS tumors were established. We aim to form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms. On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of CNS tumor diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated, and providing comprehensive resources of retrospective data and prospective cohorts for large-scale reasearches, such as classification or treatment intervention predictions.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Retrospective database of CNS tumors included in the WHO classification (2021) | – | Diagnostic Test: This study does not intervene in this process.The subtypes of brain tumors were confirmed by the postoperative histopathology or molecular pathology |
| Prospective cohort of suspected CNS tumors | – | Diagnostic Test: This study does not intervene in this process.Intracranial mass lesion comfirmed by preoperative neuroimaging |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- To reflect the daily practices, this study includes all patients with diffuse glioma at the beginning of the study.
Key inclusion criteria (3 listed)
- (1) a clear diagnosis of glioma based on pathological results;
- (2) The MRI sequence is complete and there are no obvious artifacts in the image;
- (3) The patient signs an informed consent form
Key exclusion criteria (4 listed)
- (1) Suffering from other neurological diseases;
- (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;
- (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;
- (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| This study does not intervene in this process.This study does not intervene in this process. | Diagnostic test | Prospective cohort of suspected CNS tumors, Retrospective database of CNS tumors included in the WHO classification (2021) |
Primary outcome
Establish standardized clinical-MRI-molecular markers database for CNS tumors
Time frame: 2022.06-2023.12
Collecting at least 50,000 retrospective data of CNS tumors patients, including preoperative brain MRI, clinical infromations, histopathology resuluts, and molecular markers, to establish a multi-modal clinical-MRI-molecular database
Establish prospective brain tumor cohort with multiomics information
Time frame: 2022.06.01-2030.12.31
Prospectively include at leaset 10,000 patients with brain space occupying lesions comfirmed by neuroimaging, recording their pre- and postoperative brain MRI, imaging diagnosis, histopathology or molecular pathology results, clinical intervention, treatment effect, and survival time.
1 secondary outcome
Accurately predicting the molecular and survival of glioma patients based on a deep learning model
Time frame: 2022.01-2024.12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
- Individual participant dataSharing planned: Yes. Clinical and MR data can be shared.
Related trials for Brain (Nervous System) Cancers
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Recruiting
Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors
Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yaou Liu, Doctor principal investigator
Beijing Tiantan Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain (Nervous System) Cancers and Glioma, run by Yaou Liu at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yaou Liu, Doctor (+86 1059975396, yaouliu80@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Establish standardized clinical-MRI-molecular markers database for CNS tumors (time frame: 2022.06-2023.12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.